GleamWall
中文EN

ETON Eton Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1710340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY100.6%
TTM net income YoY846.2%
TTM EPS YoY703.3%
Revenue 3-yr CAGR62.6%
Net income 3-yr CAGR181.6%

Margins

Gross margin69.2%
Operating margin28.8%
Net margin35.3%
FCF margin27.1%
EBITDA margin31.4%

Returns

ROE90.6%
ROA38.1%
ROIC (approx.)115.0%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets44.7%
Debt / equity0.27x
Current ratio1.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio8.8%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$79.95M$39.01M
Cost of revenue$37.21M$15.60M
Gross profit$42.74M$23.41M
R&D expense$7.76M$3.25M
SG&A expense$35.82M$22.75M
Operating income-$844,000-$2.60M
Interest expense$4.78M$2.00M
Pretax income-$4.56M-$3.81M
Income tax$43,000$15,000
Net income-$4.60M-$3.82M
EBITDA$3.20M-$1.45M
EPS (basic)-0.17-0.15
EPS (diluted)——
Balance sheet
Cash & equivalents$25.94M$14.94M
Receivables$11.76M$5.36M
Inventory$15.42M$15.23M
Current assets$60.58M$41.02M
PP&E, net$326,000$34,000
Intangibles$30.88M$34.88M
Total assets$92.11M$76.12M
Current liabilities$38.49M$19.95M
Short-term debt$8.79M$0
Long-term debt$21.77M$29.81M
Total debt$30.56M$29.81M
Total liabilities$65.96M$51.70M
Shareholders' equity$26.15M$24.43M
Net debt$4.62M$14.88M
Shares outstanding27.05M26.71M
Cash flow statement
Operating cash flow$10.52M$969,000
Capital expenditure$333,000$26,000
Free cash flow$10.19M$943,000
Investing cash flow-$333,000-$40.01M
Financing cash flow$815,000$32.59M
Depreciation & amortization$4.04M$1.15M
Stock-based compensation$5.51M$3.17M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.